List of works - Guy Griebel

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II.

scientific article published on 01 April 2002

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Bi

scientific article published in April 2002

5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone

scientific article published on 01 June 1995

5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research ⬇️

scientific article published on March 1, 1995

50 years of hurdles and hope in anxiolytic drug discovery

scientific article

A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety

scientific article published in June 1997

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents

scientific article published on 22 December 2010

AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters

scientific article

Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents

scientific article published in January 1994

Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: a mouse model of post-traumatic stress disorder (PTSD).

scientific article published on 4 March 2011

Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

scientific article

An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome

scientific article published on 01 August 1997

Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression

scientific article

Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.

scientific article published in February 2006

Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.

scientific article published on 21 September 2005

Antidepressants recruit new neurons to improve stress response regulation

scientific article

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

scientific article

Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice

scientific article

Awakening properties of newly discovered highly selective H₃ receptor antagonists in rats

scientific article published on 26 April 2012

Behavioral and neurochemical changes following predatory stress in mice.

scientific article published in September 2001

Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats

scientific article published in September 1999

Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels

scientific article published in July 1998

Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors

scientific article

Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys

scientific article published in December 1992

Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice ⬇️

scientific article published on March 1, 1991

Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists

scientific article published in May 1999

Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs

scientific article published in May 1997

Benzodiazepine and serotonergic modulation of antipredator and conspecific defense

scientific article

Beta-CCT, a selective BZ-omega1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice.

scientific article published in April 2000

Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression

scientific article

CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents

scientific article published on 2 November 2013

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia

scientific article published on 24 June 2008

Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone

scientific article published in July 1998

Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery.

scientific article

Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion.

scientific article published on December 2003

Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihyd

scientific article

Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling

scientific article

Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal

scientific article published on 04 June 2008

Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543.

scientific article

Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice

scientific article published in April 1999

Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine

scientific article published in July 1995

Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats

scientific article published on 2 June 2006

Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries

scientific article published on November 1997

Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders

scientific article

Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity.

scientific article

Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs

scientific article published in November 2005

Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal

scientific article published on 11 April 2008

Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents

scientific article published in November 2001

Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery

scientific article published on 19 September 2010

Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters

scientific article published in March 2004

Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

scientific article published in February 2005

Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice.

scientific article

Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: a factor analytic study

scientific article published in November 1996

Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.

scientific article published in January 2005

Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety

scientific article published in January 1996

Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats

scientific article published on 12 January 2013

Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam

scientific article published on 01 December 1995

Gender bias in the preclinical psychopharmacology of anxiety: male models for (predominantly) female disorders

scientific article published on 01 January 1995

Impaired memory following predatory stress in mice is improved by fluoxetine

scientific article published in January 2004

Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress

scientific article published on 8 September 2009

Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?

scientific article

Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?

scientific article published on 22 September 2011

Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents

scientific article published in January 1998

Long-lasting memory abnormalities following exposure to the mouse defense test battery: An animal model of PTSD.

scientific article published on 27 March 2015

Long-term impaired memory following predatory stress in mice.

scientific article published on 21 September 2005

Measuring normal and pathological anxiety-like behaviour in mice: a review.

scientific article

Mice deficient in cryptochrome 1 (cry1 (-/-)) exhibit resistance to obesity induced by a high-fat diet.

scientific article published on 09 April 2014

Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic.

scientific article published in May 2001

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic

scientific article published in November 2005

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? ⬇️

scientific article published on May 18, 2012

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

scientific article published on November 2003

Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders.

scientific article

New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes

scientific article published in September 1999

Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

scientific article

Optogenetics to study the circuits of fear- and depression-like behaviors: a critical analysis

scientific article published on 13 April 2014

Orphanin FQ, a novel neuropeptide with anti-stress-like activity

scientific article

Pharmacological studies on synthetic flavonoids: comparison with diazepam

scientific article

Pharmacology, Biochemistry and Behavior: the 2015 transition

scientific article published on 4 February 2015

Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?

scientific article published in October 2013

Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21,357.

scientific article published in June 1996

Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks

scientific article published on February 1996

Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.

scientific article

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

scientific article published on 16 August 2008

Prolactin similar to ectopic pituitary isograft restores responsiveness in Snell dwarf mice ⬇️

scientific article published on February 1, 1992

Risk assessment as an evolved threat detection and analysis process

scientific article

Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test

scientific article published in August 1997

SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents

scientific article

SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.

scientific article

SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit

scientific article published on 14 April 2005

SSR181507, a dopamine D₂ receptor and 5-HT(₁A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities

scientific article published on January 2011

SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats

scientific article published in June 2004

SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. [...]

scientific article

Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression

scientific article published on 12 May 2010

Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice

scientific article published in January 1990

Some critical determinants of the behaviour of rats in the elevated plus-maze.

scientific article

Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.

scientific article

Study of the modulatory activity of BZ (omega) receptor ligands on defensive behaviors in mice: evaluation of the importance of intrinsic efficacy and receptor subtype selectivity

scientific article published in January 1999

The CRF₁ receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis

scientific article published on 31 May 2012

The CRF₁ receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine

scientific article

The CRF₁ receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine

scientific article published on 12 November 2014

The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice

scientific article

The effects of compounds varying in selectivity as 5-HT(1A) receptor antagonists in three rat models of anxiety

scientific article published on July 2000

The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice

scientific article

The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition

scientific article published on 27 November 2010

The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies

scientific article published on 16 October 2012

m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice ⬇️

scientific article published on October 1, 1991

List of works by Guy Griebel

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Bi

5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone

5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research ⬇️

50 years of hurdles and hope in anxiolytic drug discovery

A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents

AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters

Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents

Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: a mouse model of post-traumatic stress disorder (PTSD).

Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome

Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression

Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.

Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.

Antidepressants recruit new neurons to improve stress response regulation

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice

Awakening properties of newly discovered highly selective H₃ receptor antagonists in rats

Behavioral and neurochemical changes following predatory stress in mice.

Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats

Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels

Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors

Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys

Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice ⬇️

Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists

Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs

Benzodiazepine and serotonergic modulation of antipredator and conspecific defense

Beta-CCT, a selective BZ-omega1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice.

Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression

CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia

Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone

Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery.

Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion.

Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihyd

Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling

Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal

Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543.

Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice

Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine

Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats

Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries

Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders

Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity.

Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs

Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal

Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents

Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery

Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters

Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice.

Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: a factor analytic study

Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.

Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety

Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats

Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam

Gender bias in the preclinical psychopharmacology of anxiety: male models for (predominantly) female disorders

Impaired memory following predatory stress in mice is improved by fluoxetine

Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress

Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?

Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?

Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents

Long-lasting memory abnormalities following exposure to the mouse defense test battery: An animal model of PTSD.

Long-term impaired memory following predatory stress in mice.

Measuring normal and pathological anxiety-like behaviour in mice: a review.

Mice deficient in cryptochrome 1 (cry1 (-/-)) exhibit resistance to obesity induced by a high-fat diet.

Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic.

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? ⬇️

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders.

New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes

Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

Optogenetics to study the circuits of fear- and depression-like behaviors: a critical analysis

Orphanin FQ, a novel neuropeptide with anti-stress-like activity

Pharmacological studies on synthetic flavonoids: comparison with diazepam

Pharmacology, Biochemistry and Behavior: the 2015 transition

Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?